Emcure Pharmaceuticals, a leading Indian pharma company announces the signing of a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based Gilead Sciences to manufacture and supply generic versions of lenacapavir. This agreement is part of a broader effort to increase global access to lenacapavir for HIV prevention and treatment, with a focus on high-incidence, resource-limited countries.
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries, primarily in low- and lower-middle-income regions. This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare.
Commenting on the development, Satish Mehta, Managing Director and CEO, Emcure Pharmaceuticals Ltd., said, "We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines. As the leader in HIV antiviral segment in covered market in India with long standing experience in supplying HIV medicines to over 100 LMIC countries, Emcure is uniquely positioned to drive impactful change in the global fight against HIV. By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide."
Emcure's commitment to affordability and quality is backed by its expertise in manufacturing complex generic drugs. This partnership highlights Emcure's role as a leading manufacturer of generic pharma products and its commitment to innovative and affordable healthcare globally.
About Lenacapavir:
Lenacapavir is approved in multiple countries for the treatment of adults with multi-drug resistant HIV in combination with other antiretrovirals. The use of lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established.
The multi-stage mechanism of action of lenacapavir is distinguishable from other currently approved classes of antiviral agents. While most antivirals act on just one stage of viral replication, lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle and has no known cross resistance exhibited in vitro to other existing drug classes.
Lenacapavir is being evaluated as a long-acting option in multiple ongoing and planned early and latestage clinical studies in Gilead's HIV prevention and treatment research program. Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in combination or as a mono agent, that help address individual needs and preferences of people and communities affected by HIV.
Shares of Emcure Pharmaceuticals Limited was last trading in BSE at Rs. 1493.75 as compared to the previous close of Rs. 1474.75. The total number of shares traded during the day was 5707 in over 813 trades.
The stock hit an intraday high of Rs. 1508.00 and intraday low of 1438.00. The net turnover during the day was Rs. 8495100.00. |
